Commercial

Worldwide Clinical Trials Selects William “Bill” Hirschman As New Head Of Global Business Development

March 30, 2017

MORRISVILLE, NC, mARCH 30, 2017 – William “Bill” Hirschman has joined the leadership team of Worldwide Clinical Trials (www.worldwide.com), one of the world’s leading, full-service contract research organizations (CROs), as Executive Vice President and head of Global Business Development. Hirschman will lead Worldwide’s growing business development organization, a large global team that includes sales, sales […]

The Pistoia Alliance Calls on the Life Sciences to Support Greater Collaboration to Overcome Technology Challenges

March 30, 2017

Machine learning, deep learning, and pre-competitive data analysis will deliver tangible benefits to patients  The Pistoia Alliance, a global, not for profit alliance that works to lower barriers to innovation in life sciences R&D, is calling upon the industry to improve collaborative efforts to use patient data to its full effect. In a series of […]

ACETO Subsidiary, Rising Pharmaceuticals, Launches Capecitabine Tablets, 150 & 500 mg

March 29, 2017

PORT WASHINGTON, N.Y., March 28, 2017 (GLOBE NEWSWIRE) — ACETO Corporation (NASDAQ:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched Capecitabine Tablets, 150 & 500 mg, an AB-rated generic version […]

Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis

March 29, 2017

TARRYTOWN, N.Y. and PARIS, March 28, 2017 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) approved DUPIXENT® (dupilumab) Injection, the first and only biologic medicine approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical […]

Biologics Market Size Worth $399.5 Billion By 2025 | Growth Rate: 3.9%: Grand View Research, Inc.

March 29, 2017

SAN FRANCISCO, March 29, 2017 /PRNewswire/ —   The global biologics market is anticipated to reach USD 399.5 billion by 2025, according to a new report by Grand View Research, Inc. Introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine anticipated to fuel demand. Ever-increasing understanding of the cell physiology and […]

Egalet Announces U.S. Food and Drug Administration Does Not Object to Egalet’s Distribution of Materials and Communications to Healthcare Professionals Regarding Abuse-Deterrent Properties of ARYMO™ ER via Intranasal Route

March 29, 2017

WAYNE, Pa., March 29, 2017 /PRNewswire/ — Egalet Corporation (Nasdaq: EGLT) (“Egalet”), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced the U.S. Food and Drug Administration (FDA) does not object to Egalet’s distribution of promotional materials and communications to healthcare professionals regarding […]

Immune-Onc Therapeutics, Inc. Announces Licensing and Collaboration With Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center to Develop Novel Cancer Immunotherapy

March 29, 2017

PALO ALTO, Calif.–(BUSINESS WIRE)–Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a newly established biopharmaceutical company focused on advancing promising immuno-oncology therapeutics, announced today that it has entered into an exclusive worldwide license agreement with Albert Einstein College of Medicine (“Einstein”) and Memorial Sloan Kettering Cancer Center (“MSK”). Immune-Onc Therapeutics announces licensing & collaboration with Einstein College of Medicine […]

VERIFY BRAND PLATFORM 8.0 BUILDS ON LONG-STANDING SUPPORT FOR GS1 DATA STANDARDS; HELPS COMPANIES ENABLE DATA EXCHANGE WITH EPCIS 1.2

March 29, 2017

MINNEAPOLIS – March 28, 2017 – Verify Brand, a leader in serialization and traceability software for pharmaceutical and consumer product goods companies, has announced enhancements to its serialization platform. Version 8.0 of the Verify Platform includes user-friendly, real-time analytics for better business insights, as well as updates to existing functionality of the software’s GS1 EPCIS […]

FDA Approves Genentech’s Ocrevus™ (Ocrelizumab) For Relapsing and Primary Progressive Forms of Multiple Sclerosis

March 29, 2017

SOUTH SAN FRANCISCO, Calif. – March 28, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. The majority of people with […]

Amgen Enters Into Agreement With Inovalon and Avalere to Engage Value-Based Contracting Opportunities

March 29, 2017

BOWIE, Md., March 29, 2017 (GLOBE NEWSWIRE) — Inovalon (Nasdaq:INOV), a leading technology company providing advanced, cloud-based platforms empowering a data-driven transformation from volume-based to value-based models across the healthcare ecosystem, today announced it has entered into an agreement with Amgen, one of the world’s leading independent biotechnology companies and leader in instituting innovative, value-based […]

Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24

March 28, 2017

Krakow, Poland / Berlin, Germany, March 28, 2017 / B3C newswire / — Selvita S.A. (WSE:SLV), and Berlin-Chemie Menarini, a company of the Menarini Group, announced today that both companies have entered into a global license agreement for SEL24, a dual PIM/FLT3 inhibitor currently in Phase I/II trials in acute myeloid leukemia (AML) patients. SEL24 […]

Antipsychotic Drugs Market Size to Reach USD 14.4 Billion by 2025: Grand View Research, Inc.

March 27, 2017

SAN FRANCISCO, March 27, 2017 /PRNewswire/ —   The global antipsychotic drugs market is expected to reach USD 14.4 billion by 2025, according to a new report by Grand View Research, Inc. The continuous development of better next-generation products to overcome adverse effects and unwanted reactions of existing products is creating demand for newer products. […]

Infiniti Research Identifies New Market Opportunities for Rheumatology Centers Across North America and Europe in Latest Study

March 27, 2017

LONDON–(BUSINESS WIRE)–For those without a strong government-supported healthcare structure, drug prices can be prohibitive. While this tends to benefit the pharmaceutical companies providing those drugs, it can have a significant negative impact on patient quality of life. Because of this issue, the United States is putting forward laws that will increase competition in the market. […]

XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA)

March 27, 2017

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) oral tablets in combination with methotrexate (MTX) for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or […]

XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA)

March 27, 2017

NEW YORK, N.Y., March 27, 2017 – Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) oral tablets in combination with methotrexate (MTX) for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who […]

FEEDBACK